Welcome

Hemophilia A without inhibitors remains an unmet medical need

HAVEN 3: Phase 3 study of emicizumab prophylaxis in persons with hemophilia A without inhibitors

HAVEN 4: Phase 3 study of emicizumab prophylaxis given every 4 weeks in persons with hemophilia A with and without inhibitors; additional comments

Q&A

Karl Mahler, Head of Investor Relations

Cristin Hubbard, Lifecycle Leader Hemlibra (emicizumab)

Johnny Mahlangu, MBBCh, MMed, Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa

Gallia Levy, MD, Associate Group Medical Director Hematology